178 related articles for article (PubMed ID: 28857842)
1. Relapsed/refractory acute myeloid leukemia: any progress?
Schlenk RF; Müller-Tidow C; Benner A; Kieser M
Curr Opin Oncol; 2017 Nov; 29(6):467-473. PubMed ID: 28857842
[TBL] [Abstract][Full Text] [Related]
2. Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia.
Ma J; Ge Z
Bosn J Basic Med Sci; 2021 Aug; 21(4):409-421. PubMed ID: 33577442
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
[TBL] [Abstract][Full Text] [Related]
6. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
[TBL] [Abstract][Full Text] [Related]
7. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; Bergua J; Infante J; Esteve J; Guimaraes JE; Sierra J; Sanz MÁ
Ann Hematol; 2019 Nov; 98(11):2467-2483. PubMed ID: 31667544
[TBL] [Abstract][Full Text] [Related]
8. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
10. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD).
Brunet S; Martino R; Sierra J
Curr Opin Oncol; 2013 Mar; 25(2):195-204. PubMed ID: 23385863
[TBL] [Abstract][Full Text] [Related]
13. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Rautenberg C; Nachtkamp K; Dienst A; Schmidt PV; Heyn C; Kondakci M; Germing U; Haas R; Kobbe G; Schroeder T
Eur J Haematol; 2017 Apr; 98(4):348-354. PubMed ID: 27893163
[TBL] [Abstract][Full Text] [Related]
16. A review of treatment options employed in relapsed/refractory AML.
Mohamed Jiffry MZ; Kloss R; Ahmed-Khan M; Carmona-Pires F; Okam N; Weeraddana P; Dharmaratna D; Dandwani M; Moin K
Hematology; 2023 Dec; 28(1):2196482. PubMed ID: 37036019
[TBL] [Abstract][Full Text] [Related]
17. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
18. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia.
Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A
Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014
[TBL] [Abstract][Full Text] [Related]
19. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
20. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]